咪唑立宾防治肾移植急性排斥疗效观察  

Effect of Anti-acute Rejection with Mizoribine in Renal Transplantation

作　　者：韩林[1] 李金陵[1] 

机构地区：[1]郑州市第七人民医院泌尿科,郑州市450006

出　　处：《医药论坛杂志》2005年第1期10-11,共2页Journal of Medical Forum

摘　　要：目的　观察咪唑立宾(mizoribine,MZR)在肾移植术后排斥反应的效果及不良反应。方法　56例肾移植受者术后服用MZR作为观察组。56例肾移植受者术后服用霉酚酸酯 (MMF)作为对照组。两组同时合用环孢素(CsA)和强的松(Pred),组成三联免疫抑制方案,术后随访观察 12个月。结果　观察组肾移植术后 6个月急性排斥发生率 20%, 1年内人 /肾存活率 93%。发生肝不良反应 2例 ( 3. 57% ),肾不良反应 1例(1. 78% ),消化道症状 11例(20% ),骨髓抑制 5例 (8. 92% )。对照组排斥发生率 24%,人 /肾存活率 91%。结论　咪唑立宾近期疗效稳定,确切可靠,且不良反应小,具有重大临床应用价值及社会经济效益。Objective To know effects of mizoribine(MZR) on acute rejection in the early post-transplantation period and drug toxicity and side effects. Methods 56 patients in the post transplantation oral taking MZR was observation group. 56 patients in the posttransplantation oral taking MMF for control group . The two groups combined CsA and Pred . Make up immunosuppressive plan . Observation of post transplantation were followed-up for at least 12months. Results 6 months after renal transplantation the acute rejection rate is 20% in the observation group. The man/kidney survival rate is 93%in a year. 2(3.57%) patients was found liver-toxicity and 1(1.78%) patient was found kidney-toxicity. Gastrointestinal reactions 11cases(20%). Marrow suppressive 5 cases (8.92%)。Rejection rate of control group is 24%,man/kidney survival rate 91%. Conclusion MZR is effective and safe for renal transplantation in the near furture,less toxicity and side effects, significant clinical and social economical value.

关 键 词：肾移植 咪唑立宾 急性排斥 

分 类 号：R692.5[医药卫生—泌尿科学]